Cerevel Therapeutics Holdings (CERE) Peer Comparison

$44.96

$0.00 (0.00%)

As on 01-Aug-2024 09:30EDT

Market cap

$8,191 Mln

Revenue (TTM)

$16 Mln

P/E Ratio

--

P/B Ratio

14.5

Div. Yield

0 %

Edit

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
Market cap ($ Mln)	8,191	2
Revenue ($ Mln)	16	12
Net Profit ($ Mln)	-460.47	-35.03
Net Margin (%)	-2,792.07	-291.89
RoE (%)	-109.97	--
Price to Earnings	--	--
Price-To-Book	14.51	2.14

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
Operating Revenue	16.49	12.00
Cost of Revenue	5.85	0.00
Gross Profit	-5.63	11.65
Operating Expenses	488.87	46.85
Operating Profit (EBIT)	-490.37	-34.85
Other Income	0.00	0.00
Profit before Tax	-459.91	-34.90
Provision for Tax	0.56	0.13
Profit after Tax (Net Income)	-460.47	-35.03
Minority Interest	0.00	0.00
Consolidated Profit	-99.54	-1.89

Liabilities ($ Mln)

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
Shareholder's Funds	564.46	-17.96
Minority Interest	0.00	0.00
Non-Current Liabilities	478.78	19.35
Current Liabilities	84.10	19.60
Total Liabilities	1,243.30	24.63

Assets ($ Mln)

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
Non-Current Assets	267.77	0.41
Current Assets	859.58	20.58
Total Assets	1,243.30	24.63
Total Debt*	368.30	26.67
Net Current Assets	775.47	0.97

Cashflow ($ Mln)

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
Cash From Operating Activities	-342.30	-46.36
Cash Flow from Investing Activities	--	-0.01
Cash from Financing Activities	548.62	10.72
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
ROCE (%)	-42.38	-148.58
ROE (%)	-109.97	1,796.92
ROA (%)	-41.77	-56.43
EBIT Margin (%)	-2,791.72	-184.02
Net Margin (%)	-2,792.07	-291.89
Cash Profit Margin (%)	0.00	--

Growth Ratios

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
Revenue Growth (%)	--	0.00
EBIT Growth (%)	-15.48	59.18
Net Profit Growth (%)	-18.12	38.99
EPS Growth (%)	-8.93	69.97
Book Value Growth (%)	12.79	-244.26

Valuation Ratios

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
Price / Earnings	-15.87	-5.19
Price / Book Value	10.19	-17.28
Dividend Yield (%)	--	--
EV/EBITDA	-13.10	-5.42
Market Cap ($ Cr)	--	--

Solvency Ratios

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
Debt to Equity	0.60	-1.08
Short term debt to equity ratio	0.01	-0.41
Current Ratio	10.22	1.05
Quick Ratio	10.12	1.05
Interest Coverage	-42.46	-7.91

Operating Efficiency Ratios

	Cerevel Therapeutics Holdings (CERE)	ASLAN Pharmaceuticals - ADR
Debtors to sales (%)	30.09	1.43
Asset Turnover	0.01	0.19
Receivable days	--	5.22
Inventory Days	-132.81	--
Payable days	711.55	10,849.14
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly